KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Share-based Compensation (2016 - 2025)

BeOne Medicines (ONC) has disclosed Share-based Compensation for 11 consecutive years, with $140.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation rose 22.77% to $140.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $494.7 million, a 15.88% increase, with the full-year FY2024 number at $441.6 million, up 20.13% from a year prior.
  • Share-based Compensation was $140.8 million for Q3 2025 at BeOne Medicines, down from $150.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $150.8 million in Q2 2025 to a low of $45.8 million in Q1 2021.
  • A 5-year average of $91.6 million and a median of $88.7 million in 2024 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: surged 43.03% in 2022, then rose 7.68% in 2025.
  • BeOne Medicines' Share-based Compensation stood at $63.0 million in 2021, then grew by 23.99% to $78.1 million in 2022, then grew by 18.94% to $92.9 million in 2023, then rose by 15.82% to $107.6 million in 2024, then soared by 30.84% to $140.8 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Share-based Compensation are $140.8 million (Q3 2025), $150.8 million (Q2 2025), and $95.5 million (Q1 2025).